Litex Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 21-12-2024
- Paid Up Capital ₹ 0.20 M
as on 21-12-2024
- Company Age 36 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 M
as on 21-12-2024
- Revenue 32.00%
(FY 2022)
- Profit 87.89%
(FY 2022)
- Ebitda -45.58%
(FY 2022)
- Net Worth 19.54%
(FY 2022)
- Total Assets -1.87%
(FY 2022)
About Litex Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹5.00 M.
Kusum Thakur and Ajay Thakur serve as directors at the Company.
- CIN/LLPIN
U74899DL1988PTC030484
- Company No.
030484
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Feb 1988
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Litex Pharmaceuticals Private Limited offer?
Litex Pharmaceuticals Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, HIV Drugs, Antiviral Drugs, Cardiovascular Drugs & Medication, Diabetes Medicine, Common Disease Medicines, Steroid, Pain Relief Drugs & Pharmaceuticals, Arthritic Drugs, TB, Tumor & Cancer Drugs.
Who are the key members and board of directors at Litex Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kusum Thakur  | Director | 17-Feb-2020 | Current |
| Ajay Thakur | Director | 01-Apr-2000 | Current |
Financial Performance of Litex Pharmaceuticals.
Litex Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 32% increase. The company also saw a substantial improvement in profitability, with a 87.89% increase in profit. The company's net worth Soared by an impressive increase of 19.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Litex Pharmaceuticals?
In 2022, Litex Pharmaceuticals had a promoter holding of 90.00% and a public holding of 10.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 08 Jan 2024 | ₹5.00 M | Open |
How Many Employees Work at Litex Pharmaceuticals?
Unlock and access historical data on people associated with Litex Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Litex Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Litex Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
